{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,7,15]],"date-time":"2026-07-15T12:11:27Z","timestamp":1784117487991,"version":"3.55.0"},"reference-count":110,"publisher":"Informa UK Limited","issue":"10","license":[{"start":{"date-parts":[[2026,6,29]],"date-time":"2026-06-29T00:00:00Z","timestamp":1782691200000},"content-version":"vor","delay-in-days":0,"URL":"http:\/\/creativecommons.org\/licenses\/by-nc-nd\/4.0\/"},{"start":{"date-parts":[[2026,6,29]],"date-time":"2026-06-29T00:00:00Z","timestamp":1782691200000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/doi.org\/10.1080\/policies-text-data-mining"}],"content-domain":{"domain":["www.tandfonline.com"],"crossmark-restriction":true},"short-container-title":["Expert Opinion on Pharmacotherapy"],"published-print":{"date-parts":[[2026,7,3]]},"DOI":"10.1080\/14656566.2026.2695099","type":"journal-article","created":{"date-parts":[[2026,6,26]],"date-time":"2026-06-26T13:49:59Z","timestamp":1782481799000},"page":"979-993","update-policy":"https:\/\/doi.org\/10.1080\/tandf_crossmark_01","source":"Crossref","is-referenced-by-count":0,"title":["Pharmacotherapeutic strategies for the management of congenital adrenal hyperplasia"],"prefix":"10.1080","volume":"27","author":[{"ORCID":"https:\/\/orcid.org\/0009-0004-6435-0066","authenticated-orcid":false,"given":"Wen Huey","family":"Goai","sequence":"first","affiliation":[{"name":"Adelaide University","place":["Adelaide, Australia"]},{"name":"Royal Adelaide Hospital","place":["Adelaide, Australia"]}],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0002-5069-0981","authenticated-orcid":false,"given":"David J.","family":"Torpy","sequence":"additional","affiliation":[{"name":"Adelaide University","place":["Adelaide, Australia"]},{"name":"Royal Adelaide Hospital","place":["Adelaide, Australia"]}],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"301","published-online":{"date-parts":[[2026,6,29]]},"reference":[{"key":"e_1_3_4_3_1","doi-asserted-by":"publisher","DOI":"10.1210\/endrev\/bnab016"},{"key":"e_1_3_4_4_1","doi-asserted-by":"publisher","DOI":"10.1038\/nrendo.2013.239"},{"key":"e_1_3_4_5_1","doi-asserted-by":"publisher","DOI":"10.1016\/j.ecl.2017.01.008"},{"key":"e_1_3_4_6_1","doi-asserted-by":"publisher","DOI":"10.1210\/clinem\/dgae563"},{"key":"e_1_3_4_7_1","doi-asserted-by":"publisher","DOI":"10.1016\/j.ecl.2020.10.008"},{"key":"e_1_3_4_8_1","doi-asserted-by":"publisher","DOI":"10.1210\/jc.2018-01865"},{"key":"e_1_3_4_9_1","doi-asserted-by":"publisher","DOI":"10.1159\/000526468"},{"key":"e_1_3_4_10_1","doi-asserted-by":"publisher","DOI":"10.1080\/17446651.2025.2450423"},{"key":"e_1_3_4_11_1","doi-asserted-by":"publisher","DOI":"10.1002\/14651858.CD012517.pub2"},{"key":"e_1_3_4_12_1","doi-asserted-by":"publisher","DOI":"10.1186\/s13633-016-0035-5"},{"key":"e_1_3_4_13_1","doi-asserted-by":"publisher","DOI":"10.1590\/S0004-27302004000500017"},{"key":"e_1_3_4_14_1","doi-asserted-by":"publisher","DOI":"10.1210\/jc.2008-0519"},{"key":"e_1_3_4_15_1","doi-asserted-by":"publisher","DOI":"10.1016\/S0022-3476(85)80486-8"},{"key":"e_1_3_4_16_1","doi-asserted-by":"publisher","DOI":"10.4274\/jcrpe.galenos.2023.2023-3-5"},{"key":"e_1_3_4_17_1","doi-asserted-by":"publisher","DOI":"10.1210\/clinem\/dgab133"},{"key":"e_1_3_4_18_1","doi-asserted-by":"publisher","DOI":"10.1210\/js.2019-00136"},{"key":"e_1_3_4_19_1","doi-asserted-by":"publisher","DOI":"10.1210\/jc.2014-4124"},{"issue":"3","key":"e_1_3_4_20_1","first-page":"360","article-title":"Long-term prednisone versus hydrocortisone treatment in children with classic Congenital Adrenal Hyperplasia (CAH) and a brief review of the literature","volume":"90","author":"Ahmed SEAM","year":"2019","unstructured":"Ahmed SEAM, Soliman AT, Ramadan MA, et al. Long-term prednisone versus hydrocortisone treatment in children with classic Congenital Adrenal Hyperplasia (CAH) and a brief review of the literature. Acta Biomedica Atenei Parmensis. 2019;90(3):360\u2013369.","journal-title":"Acta Biomedica Atenei Parmensis"},{"key":"e_1_3_4_21_1","doi-asserted-by":"publisher","DOI":"10.1210\/clinem\/dgad628"},{"key":"e_1_3_4_22_1","doi-asserted-by":"publisher","DOI":"10.1136\/adc.77.3.214"},{"key":"e_1_3_4_23_1","doi-asserted-by":"publisher","DOI":"10.3803\/EnM.2021.1328"},{"key":"e_1_3_4_24_1","doi-asserted-by":"publisher","DOI":"10.1210\/jc.2010-0917"},{"key":"e_1_3_4_25_1","doi-asserted-by":"publisher","DOI":"10.1530\/EJE-20-1249"},{"key":"e_1_3_4_26_1","doi-asserted-by":"publisher","DOI":"10.1297\/cpe.2022-0009"},{"key":"e_1_3_4_27_1","doi-asserted-by":"publisher","DOI":"10.3390\/jcm12093128"},{"key":"e_1_3_4_28_1","doi-asserted-by":"publisher","DOI":"10.1210\/jc.2006-2109"},{"key":"e_1_3_4_29_1","doi-asserted-by":"publisher","DOI":"10.1016\/j.jpeds.2014.01.011"},{"key":"e_1_3_4_30_1","doi-asserted-by":"publisher","DOI":"10.1067\/S0022-3476(03)00294-4"},{"key":"e_1_3_4_31_1","doi-asserted-by":"publisher","DOI":"10.1210\/endrev\/bnaa002"},{"key":"e_1_3_4_32_1","doi-asserted-by":"publisher","DOI":"10.1111\/j.1365-2265.2006.02544.x"},{"key":"e_1_3_4_33_1","doi-asserted-by":"publisher","DOI":"10.1530\/EJE-07-0052"},{"key":"e_1_3_4_34_1","doi-asserted-by":"publisher","DOI":"10.5402\/2011\/219494"},{"key":"e_1_3_4_35_1","doi-asserted-by":"publisher","DOI":"10.1210\/jc.2009-0630"},{"key":"e_1_3_4_36_1","doi-asserted-by":"publisher","DOI":"10.1210\/jc.2016-1916"},{"key":"e_1_3_4_37_1","doi-asserted-by":"publisher","DOI":"10.1111\/cen.13813"},{"key":"e_1_3_4_38_1","doi-asserted-by":"publisher","DOI":"10.1530\/EC-25-0696"},{"key":"e_1_3_4_39_1","doi-asserted-by":"publisher","DOI":"10.1111\/j.1365-2265.2009.03636.x"},{"key":"e_1_3_4_40_1","doi-asserted-by":"publisher","DOI":"10.1210\/jc.2014-3809"},{"key":"e_1_3_4_41_1","doi-asserted-by":"publisher","DOI":"10.1210\/clinem\/dgab051"},{"key":"e_1_3_4_42_1","doi-asserted-by":"publisher","DOI":"10.1530\/EC-24-0150"},{"key":"e_1_3_4_43_1","doi-asserted-by":"publisher","DOI":"10.1093\/ejendo\/lvaf130"},{"key":"e_1_3_4_44_1","doi-asserted-by":"publisher","DOI":"10.1210\/clinem\/dgae822"},{"key":"e_1_3_4_45_1","doi-asserted-by":"publisher","DOI":"10.1210\/jc.2011-1926"},{"key":"e_1_3_4_46_1","doi-asserted-by":"publisher","DOI":"10.1007\/s40265-025-02216-7"},{"key":"e_1_3_4_47_1","doi-asserted-by":"publisher","DOI":"10.1530\/EC-24-0619"},{"key":"e_1_3_4_48_1","doi-asserted-by":"publisher","DOI":"10.1016\/j.eclinm.2025.103714"},{"key":"e_1_3_4_49_1","doi-asserted-by":"publisher","DOI":"10.1136\/bmjpo-2017-000198"},{"key":"e_1_3_4_50_1","doi-asserted-by":"publisher","DOI":"10.1530\/EJE-17-0248"},{"key":"e_1_3_4_51_1","doi-asserted-by":"publisher","DOI":"10.1210\/jendso\/bvaa091"},{"key":"e_1_3_4_52_1","doi-asserted-by":"publisher","DOI":"10.1080\/21678707.2021.1903871"},{"key":"e_1_3_4_53_1","doi-asserted-by":"publisher","DOI":"10.1210\/jc.2014-4060"},{"key":"e_1_3_4_54_1","doi-asserted-by":"publisher","DOI":"10.1210\/js.2018-00380"},{"key":"e_1_3_4_55_1","doi-asserted-by":"publisher","DOI":"10.1111\/cen.13447"},{"key":"e_1_3_4_56_1","doi-asserted-by":"publisher","DOI":"10.1210\/clinem\/dgaa626"},{"key":"e_1_3_4_57_1","doi-asserted-by":"publisher","DOI":"10.1210\/jc.2015-3574"},{"key":"e_1_3_4_58_1","doi-asserted-by":"publisher","DOI":"10.1016\/j.endmts.2025.100247"},{"key":"e_1_3_4_59_1","doi-asserted-by":"publisher","DOI":"10.1210\/clinem\/dgab749"},{"key":"e_1_3_4_60_1","doi-asserted-by":"publisher","DOI":"10.1056\/NEJMoa2404656"},{"issue":"1","key":"e_1_3_4_61_1","article-title":"SUN-417 crinecerfont maintains adrenocorticotropic hormone and 17-hydroxyprogesterone levels with reduced glucocorticoid doses in adults with classic congenital adrenal hyperplasia: 1-year results from the CAHtalystTM adult study","volume":"9","author":"Auchus RJ","year":"2025","unstructured":"Auchus RJ, Hamidi O, Liu C, et al. SUN-417 crinecerfont maintains adrenocorticotropic hormone and 17-hydroxyprogesterone levels with reduced glucocorticoid doses in adults with classic congenital adrenal hyperplasia: 1-year results from the CAHtalystTM adult study. J Endocr Soc. 2025;9(Supplement_1):bvaf149.387.","journal-title":"J Endocr Soc"},{"issue":"1","key":"e_1_3_4_62_1","article-title":"SUN-414 crinecerfont improves reproductive hormones in classic congenital adrenal hyperplasia: 1-year results from the phase 3 CAHtalystTM adult study","volume":"9","author":"Merke DP","year":"2025","unstructured":"Merke DP, Vaid S, Salam M, et al. SUN-414 crinecerfont improves reproductive hormones in classic congenital adrenal hyperplasia: 1-year results from the phase 3 CAHtalystTM adult study. J Endocr Soc. 2025;9(Supplement_1):bvaf149.384.","journal-title":"J Endocr Soc"},{"issue":"1","key":"e_1_3_4_63_1","article-title":"SUN-416 crinecerfont improves clinical outcomes in adults with classic congenital adrenal hyperplasia: 1-year results from the CAHtalystTM adult study","volume":"9","author":"Auchus RJ","year":"2025","unstructured":"Auchus RJ, Hamidi O, Bancos I, et al. SUN-416 crinecerfont improves clinical outcomes in adults with classic congenital adrenal hyperplasia: 1-year results from the CAHtalystTM adult study. J Endocr Soc. 2025;9(Supplement_1):bvaf149.386.","journal-title":"J Endocr Soc"},{"key":"e_1_3_4_64_1","doi-asserted-by":"publisher","DOI":"10.1210\/clinem\/dgad270"},{"key":"e_1_3_4_65_1","doi-asserted-by":"publisher","DOI":"10.1056\/NEJMoa2404655"},{"key":"e_1_3_4_66_1","doi-asserted-by":"publisher","DOI":"10.1210\/jendso\/bvaf149.271"},{"key":"e_1_3_4_67_1","doi-asserted-by":"publisher","DOI":"10.1210\/jendso\/bvaf149.404"},{"key":"e_1_3_4_68_1","doi-asserted-by":"publisher","DOI":"10.1210\/clinem\/dgab438"},{"key":"e_1_3_4_69_1","unstructured":"Spruce biosciences announces topline results from CAHmelia-204 in Adult CAH and CAHptain-205 in adult and pediatric CAH | Spruce Biosciences [Internet]. [cited 2026 Apr 3]. Available from: https:\/\/investors.sprucebio.com\/news-releases\/news-release-details\/spruce-biosciences-announces-topline-results-cahmelia-204-adult\/"},{"key":"e_1_3_4_70_1","doi-asserted-by":"publisher","DOI":"10.1021\/acsmedchemlett.3c00514"},{"key":"e_1_3_4_71_1","doi-asserted-by":"publisher","DOI":"10.1530\/endoabs.86.P344"},{"key":"e_1_3_4_72_1","doi-asserted-by":"publisher","DOI":"10.1210\/jendso\/bvac150.172"},{"issue":"1","key":"e_1_3_4_73_1","article-title":"OR07-06 once-daily oral atumelnant (CRN04894) induces rapid, substantial, and sustained reductions of androstenedione and 17-hydroxyprogesterone in adults with classical congenital adrenal hyperplasia: interim results from a 12-week, phase 2, open-label study","volume":"9","author":"Srirangalingam U","year":"2025","unstructured":"Srirangalingam U, Bruera D, Ayala A, et al. OR07-06 once-daily oral atumelnant (CRN04894) induces rapid, substantial, and sustained reductions of androstenedione and 17-hydroxyprogesterone in adults with classical congenital adrenal hyperplasia: interim results from a 12-week, phase 2, open-label study. J Endocr Soc. 2025;9(Supplement_1):bvaf149.272.","journal-title":"J Endocr Soc"},{"key":"e_1_3_4_74_1","unstructured":"Crinetics announces strong PALSONIFY launch execution and positive results for concurrent androstenedione lowering and glucocorticoid dose reduction in phase 2 trial of atumelnant for congenital adrenal hyperplasia [Internet]. Crinetics. 2026 [cited 2026 Apr 4]. Available from: https:\/\/crinetics.com\/crinetics-announces-strong-palsonify-launch-execution-and-positive-results-for-concurrent-androstenedione-lowering-and-glucocorticoid-dose-reduction-in-phase-2-trial-of-atumelnant-for-congenital-adren\/"},{"key":"e_1_3_4_75_1","doi-asserted-by":"publisher","DOI":"10.1210\/en.2016-1455"},{"key":"e_1_3_4_76_1","doi-asserted-by":"publisher","DOI":"10.1210\/en.2019-00117"},{"key":"e_1_3_4_77_1","doi-asserted-by":"publisher","DOI":"10.1210\/jendso\/bvaf149.226"},{"key":"e_1_3_4_78_1","doi-asserted-by":"publisher","DOI":"10.1210\/jendso\/bvaf149.323"},{"issue":"10","key":"e_1_3_4_79_1","first-page":"3535","article-title":"A preliminary study of flutamide, testolactone, and reduced hydrocortisone dose in the treatment of congenital adrenal hyperplasia","volume":"81","author":"Laue L","year":"1996","unstructured":"Laue L, Merke DP, Jones JV, et al. A preliminary study of flutamide, testolactone, and reduced hydrocortisone dose in the treatment of congenital adrenal hyperplasia. J Clin Endocrinol Metab. 1996;81(10):3535\u20133539.","journal-title":"J Clin Endocrinol Metab"},{"key":"e_1_3_4_80_1","doi-asserted-by":"publisher","DOI":"10.1210\/jcem.85.3.6462"},{"key":"e_1_3_4_81_1","doi-asserted-by":"publisher","DOI":"10.1210\/clinem\/dgae824"},{"key":"e_1_3_4_82_1","doi-asserted-by":"publisher","DOI":"10.1016\/j.biopha.2018.02.067"},{"key":"e_1_3_4_83_1","doi-asserted-by":"publisher","DOI":"10.1210\/jc.2011-2189"},{"key":"e_1_3_4_84_1","doi-asserted-by":"publisher","DOI":"10.1210\/jc.2014-1258"},{"key":"e_1_3_4_85_1","doi-asserted-by":"publisher","DOI":"10.1530\/EJE-19-0905"},{"key":"e_1_3_4_86_1","doi-asserted-by":"publisher","DOI":"10.1210\/jcemcr\/luae077"},{"key":"e_1_3_4_87_1","doi-asserted-by":"publisher","DOI":"10.4274\/jcrpe.v1i6.256"},{"key":"e_1_3_4_88_1","doi-asserted-by":"publisher","DOI":"10.1111\/cen.14009"},{"key":"e_1_3_4_89_1","doi-asserted-by":"publisher","DOI":"10.1210\/clinem\/dgae771"},{"key":"e_1_3_4_90_1","doi-asserted-by":"publisher","DOI":"10.1186\/s12887-025-05703-8"},{"key":"e_1_3_4_91_1","doi-asserted-by":"publisher","DOI":"10.1038\/nrendo.2011.161"},{"key":"e_1_3_4_92_1","doi-asserted-by":"publisher","DOI":"10.1159\/000546576"},{"key":"e_1_3_4_93_1","doi-asserted-by":"publisher","DOI":"10.3390\/cancers16234061"},{"key":"e_1_3_4_94_1","doi-asserted-by":"publisher","DOI":"10.1056\/NEJMc1410041"},{"key":"e_1_3_4_95_1","doi-asserted-by":"publisher","DOI":"10.1530\/EJE-20-0787"},{"key":"e_1_3_4_96_1","doi-asserted-by":"publisher","DOI":"10.1210\/en.2015-2052"},{"key":"e_1_3_4_97_1","doi-asserted-by":"publisher","DOI":"10.1210\/clinem\/dgaa381"},{"key":"e_1_3_4_98_1","doi-asserted-by":"publisher","DOI":"10.37349\/eemd.2024.00011"},{"key":"e_1_3_4_99_1","doi-asserted-by":"publisher","DOI":"10.1038\/sj.gt.3301018"},{"key":"e_1_3_4_100_1","doi-asserted-by":"publisher","DOI":"10.1038\/gt.2017.10"},{"key":"e_1_3_4_101_1","doi-asserted-by":"publisher","DOI":"10.1089\/hum.2017.203"},{"key":"e_1_3_4_102_1","doi-asserted-by":"publisher","DOI":"10.1507\/endocrj.EJ16-0112"},{"key":"e_1_3_4_103_1","doi-asserted-by":"publisher","DOI":"10.1016\/j.omtm.2024.101232"},{"key":"e_1_3_4_104_1","doi-asserted-by":"publisher","DOI":"10.1210\/jendso\/bvaa046.899"},{"key":"e_1_3_4_105_1","unstructured":"Bridgebio pharma reports topline results from phase 1\/2 trial of investigational gene therapy for congenital adrenal hyperplasia (cah) [Internet]. [cited 2026 Apr 6]. Available from: https:\/\/investor.bridgebio.com\/news\/news-details\/2024\/bridgebio-pharma-reports-topline-results-from-phase-12-trial-of-investigational-gene-therapy-for-congenital-adrenal-hyperplasia-cah-09-10-2024\/default.aspx"},{"key":"e_1_3_4_106_1","doi-asserted-by":"publisher","DOI":"10.1016\/j.ymthe.2025.11.011"},{"key":"e_1_3_4_107_1","doi-asserted-by":"publisher","DOI":"10.1016\/j.hctj.2024.100057"},{"key":"e_1_3_4_108_1","doi-asserted-by":"publisher","DOI":"10.1530\/EC-25-0565"},{"key":"e_1_3_4_109_1","doi-asserted-by":"publisher","DOI":"10.1210\/jc.2014-2433"},{"key":"e_1_3_4_110_1","doi-asserted-by":"publisher","DOI":"10.1210\/jc.2013-4253"},{"key":"e_1_3_4_111_1","doi-asserted-by":"publisher","DOI":"10.1210\/clinem\/dgz002"},{"key":"e_1_3_4_112_1","doi-asserted-by":"publisher","DOI":"10.1177\/10600280251396594"}],"container-title":["Expert Opinion on Pharmacotherapy"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/www.tandfonline.com\/doi\/pdf\/10.1080\/14656566.2026.2695099","content-type":"application\/pdf","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/www.tandfonline.com\/doi\/full-xml\/10.1080\/14656566.2026.2695099","content-type":"application\/xml","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/www.tandfonline.com\/doi\/pdf\/10.1080\/14656566.2026.2695099","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2026,7,15]],"date-time":"2026-07-15T11:37:58Z","timestamp":1784115478000},"score":1,"resource":{"primary":{"URL":"https:\/\/www.tandfonline.com\/doi\/full\/10.1080\/14656566.2026.2695099"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2026,6,29]]},"references-count":110,"journal-issue":{"issue":"10","published-print":{"date-parts":[[2026,7,3]]}},"alternative-id":["10.1080\/14656566.2026.2695099"],"URL":"https:\/\/doi.org\/10.1080\/14656566.2026.2695099","relation":{},"ISSN":["1465-6566","1744-7666"],"issn-type":[{"value":"1465-6566","type":"print"},{"value":"1744-7666","type":"electronic"}],"subject":[],"published":{"date-parts":[[2026,6,29]]},"assertion":[{"value":"The publishing and review policy for this title is described in its Aims & Scope.","order":1,"name":"peerreview_statement","label":"Peer Review Statement"},{"value":"http:\/\/www.tandfonline.com\/action\/journalInformation?show=aimsScope&journalCode=ieop20","URL":"http:\/\/www.tandfonline.com\/action\/journalInformation?show=aimsScope&journalCode=ieop20","order":2,"name":"aims_and_scope_url","label":"Aim & Scope"},{"value":"2026-04-22","order":0,"name":"received","label":"Received","group":{"name":"publication_history","label":"Publication History"}},{"value":"2026-06-22","order":2,"name":"accepted","label":"Accepted","group":{"name":"publication_history","label":"Publication History"}},{"value":"2026-06-29","order":3,"name":"published","label":"Published","group":{"name":"publication_history","label":"Publication History"}}]}}